ARTICLE | Company News
Allergan, Peplin Ltd. deal
October 11, 2004 7:00 AM UTC
The companies ended their 2002 deal, under which AGN received North and South American rights to develop and commercialize PEP's PEP005 to treat non-melanoma skin cancer and actinic keratosis. PEP wil...